1 |
Wang N, Zhang C. Recent advances in the management of diabetic kidney disease: slowing progression[J]. Int J Mol Sci, 2024, 25(6): 3086.
|
2 |
Gupta S, Dominguez M, Golestaneh L. Diabetic kidney disease: an update[J]. Med Clin North Am, 2023, 107(4): 689-705.
|
3 |
DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors[J]. Nat Rev Nephrol, 2021, 17(5):319-34.
|
4 |
Sugahara M, Pak WLW, Tanaka T, et al. Update on diagnosis, pathophysiology, and management of diabetic kidney disease[J]. Nephrology, 2021, 26(6): 491-500.
|
5 |
Hu SW, Hang X, Wei Y, et al. Crosstalk among podocytes, glomerular endothelial cells and mesangial cells in diabetic kidney disease: an updated review[J]. Cell Commun Signal, 2024, 22(1): 136.
|
6 |
Mohandes S, Doke T, Hu HL, et al. Molecular pathways that drive diabetic kidney disease[J]. J Clin Invest, 2023, 133(4): e165654.
|
7 |
Liu SM, Yuan YG, Xue Y, et al. Podocyte injury in diabetic kidney disease: a focus on mitochondrial dysfunction[J]. Front Cell Dev Biol, 2022, 10: 832887.
|
8 |
Wu QR, Yan RZ, Yang HW, et al. Qing-Re-Xiao-Zheng-Yi-Qi formula relieves kidney damage and activates mitophagy in diabetic kidney disease[J]. Front Pharmacol, 2022, 13: 992597.
|
9 |
Li W, Du MM, Wang QZ, et al. FoxO1 promotes mitophagy in the podocytes of diabetic male mice via the PINK1/parkin pathway[J]. Endocrinology, 2017, 158(7): 2155-67.
|
10 |
Mahtal N, Lenoir O, Tinel C, et al. MicroRNAs in kidney injury and disease[J]. Nat Rev Nephrol, 2022, 18(10): 643-62.
|
11 |
Wang J, Shen LY, Hong H, et al. Atrasentan alleviates high glucose-induced podocyte injury by the microRNA-21/forkhead box O1 axis[J]. Eur J Pharmacol, 2019, 852: 142-50.
|
12 |
Ma LL, Li J, Zhang XT, et al. Chinese botanical drugs targeting mitophagy to alleviate diabetic kidney disease, a comprehensive review[J]. Front Pharmacol, 2024, 15: 1360179.
|
13 |
Li XD, Zhang Y, Xing XD, et al. Podocyte injury of diabetic nephropathy: novel mechanism discovery and therapeutic prospects[J]. Biomedecine Pharmacother, 2023, 168: 115670.
|
14 |
郭东义, 张 鹏, 卞 华, 等. 益气养阴化浊通络方对早期糖尿病肾病患者NF‑κB、MCP-1及IL-6的影响[J]. 河南中医, 2016, 36(8): 1386-8.
|
15 |
张 鹏, 吕 芹, 郭东义, 等. 益气养阴化浊通络方对早期糖尿病肾脏疾病患者内皮细胞及血液流变学的影响[J]. 科学技术与工程, 2016, 16(17): 119-22.
|
16 |
韩 立, 吕 芹, 郭东义, 等. 益气养阴化浊通络方对早期糖尿病肾脏疾病患者氧化应激的影响[J]. 科学技术与工程, 2016, 16(14): 23-6.
|
17 |
郭克磊, 李颖利, 韩 立, 等. 益气养阴化浊通络方对高糖诱导小鼠肾足细胞自噬ATG5、Beclin-1及BNIP3表达的影响[J]. 中国医院药学杂志, 2023, 43(16): 1808-13.
|
18 |
朱政洁, 马雷雷, 何立群. 从益气养阴、补肾活血论治糖尿病肾病[J]. 中华中医药杂志, 2022, 37(12):7170-3.
|
19 |
中华中医药学会, 北京中医药大学东直门医院, 北京中医药大学. 糖尿病肾脏疾病中西医结合诊疗指南[J]. 北京中医药大学学报, 2024, 47(4): 580-92.
|
20 |
Liu XQ, Jiang L, Li YY, et al. Wogonin protects glomerular podocytes by targeting Bcl-2-mediated autophagy and apoptosis in diabetic kidney disease[J]. Acta Pharmacol Sin, 2022, 43(1): 96-110.
|
21 |
Gong L, Wang R, Wang XY, et al. Research progress of natural active compounds on improving podocyte function to reduce proteinuria in diabetic kidney disease[J]. Ren Fail, 2023, 45(2): 2290930.
|
22 |
Wang SL, Long HJ, Hou LJ, et al. The mitophagy pathway and its implications in human diseases[J]. Signal Transduct Target Ther, 2023, 8(1): 304.
|
23 |
Zhang XF, Feng J, Li X, et al. Mitophagy in diabetic kidney disease[J]. Front Cell Dev Biol, 2021, 9: 778011.
|
24 |
Han R, Liu YT, Li SH, et al. PINK1-PRKN mediated mitophagy: differences between in vitro and in vivo models[J]. Autophagy, 2023, 19(5): 1396-405.
|
25 |
Han XD, Wang J, Li RL, et al. Placental mesenchymal stem cells alleviate podocyte injury in diabetic kidney disease by modulating mitophagy via the SIRT1-PGC-1alpha-TFAM pathway[J]. Int J Mol Sci, 2023, 24(5): 4696.
|
26 |
Dhas Y, Arshad N, Biswas N, et al. MicroRNA-21 silencing in diabetic nephropathy: insights on therapeutic strategies[J]. Biomedicines, 2023, 11(9): 2583.
|
27 |
Szostak J, Gor&#x; cy A, Durys D, et al. The role of microRNA in the pathogenesis of diabetic nephropathy[J]. Int J Mol Sci, 2023, 24(7): 6214.
|
28 |
Liu SJ, Wu WZ, Liao J, et al. MicroRNA-21: a critical pathogenic factor of diabetic nephropathy[J]. Front Endocrinol, 2022, 13: 895010.
|
29 |
Assmann TS, Recamonde-Mendoza M, Costa AR, et al. Circulating miRNAs in diabetic kidney disease: case-control study and in silico analyses[J]. Acta Diabetol, 2019, 56(1): 55-65.
|
30 |
向珈谊, 张会芳, 梁露群, 等. miR-21通过下调PPAR-α参与脂质代谢紊乱并促进糖尿病大鼠肾组织及肾小管上皮细胞纤维化病变[J]. 中国病理生理杂志, 2021, 37(10): 1858-67.
|
31 |
Orea-Soufi A, Paik J, Bragança J, et al. FOXO transcription factors as therapeutic targets in human diseases[J]. Trends Pharmacol Sci, 2022, 43(12): 1070-84.
|
32 |
Li XD, Wan TT, Li YB. Role of FoxO1 in regulating autophagy in type 2 diabetes mellitus (Review)[J]. Exp Ther Med, 2021, 22(1): 707.
|
33 |
Xu YM, Xu C, Huang J, et al. Astragalus polysaccharide attenuates diabetic nephropathy by reducing apoptosis and enhancing autophagy through activation of Sirt1/FoxO1 pathway[J]. Int Urol Nephrol, 2024, 56(9): 3067-78.
|